He has over 20 academic publications, inventorship on numerous patents, and serves as reviewer for multiple journals and NIH grants committee. Peter Kolchinsky, Ph.D. Emorys primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Habib Dable is a Venture Partner at RA Ventures (RAVen), focusing on advising and supporting newcos, portfolio companies and executives within RAVen. Laura holds a BA in Biology and Psychology from Harvard University, and a PhD in Neuroscience from MIT. Prior to RA, Chris was at Elsevier Business Intelligence, where he served as Writer/Editor and eventually became the Editor in Chief for Biopharmaceuticals and Consumer Products. Peter Balogh is an Analyst on the Investment Team at RA Capital Management. Special Projects Operations Manager/Chief of Staff. Michael Gillespie is an Analyst on the Venture Team at RA Capital Management. Alyssa previously worked as a Senior Scientist at Eagle Pharmaceuticals. Nandita Shangari is joining RA Capital from Novartis Venture Fund (NVF), a life science investment firm, where she was a Managing Director. Walter's primary responsibility at RA Capital is to create competitive landscapes of biotechnology and planetary health. Eric holds a MAcc from Bentley University and a BS in Finance from George Mason University. Jaimie previously held roles as data analyst at Massachusetts Department of Public Health and Anne Arundel Medical Center Department of Medicine. Dan Marks is a Principal on the Venture Team at RA Capital Management. Ana holds an MPH in Epidemiology and Biostatistics from Boston University School of Public Health and a BA in Neuroscience from Boston University. Adam was most recently President, CEO and member of the Board of Directors of Rodin Therapeutics until its acquisition by Alkermes in 2019. Prior to her Managing Director role at NVF, Nandita held various positions at Novartis in Business Development and Licensing and as a key member of the Kymriah Global Program Team, helping to bring this novel cell therapy to market. Robert Nicol is a Venture Partner at RA Ventures (RAVen), focusing on company creation. Soumya obtained his PhD in X-ray Crystallography and Biophysics from the Indian Institute of Science while working as visiting research scholar at Rockefeller University. Priscillas primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Laura has a BS in Human Services; Clinical Concentration and a Minor in Disabilities Studies from the University of Delaware. Michael has also previously held the position of Vice President and General Manager at Thomson Medstat (now part of IBM Watson Health), as well as held management roles at Immusol, a San Diego-based biotechnology company, HealthAllies, an organization created to provide discretionary medical benefits to the cash-pay market, and Da Vita, a national provider of dialysis services. Shan Shan Wang is an Associate Director within the TechAtlas division at RA Capital Management. Prior to Schrdinger, Cony was President Chief Business Officer at Proteros responsible for all commercial activities. Tess has a BA with a double major in Economics and Peace & Conflict studies from the University of Toronto, Canada. Soumya spent time as an EIR at IncTank Ventures, where he worked on multiple company creations. In this role, he works closely with the RA Venture team to evaluate and incubate early-stage therapeutic programs. in Business Administration in Management with a Minor in Biology from UMass Amherst Commonwealth Honors College. Earlier in his career, he was Head of Early Analytical Development for Novartis Cell and Gene Therapies Unit and worked on research teams at the National Cancer Institute with Dr. Steven Rosenberg, the University of Pennsylvania Gene Therapy Program with Dr. Jim Wilson, and Johnson and Johnsons Immunology Discovery group. Pieters primary responsibility at RA Capital is to lead major strategic initiatives and drive operational excellence across the firm. Brendan has more than 18 years of experience as a tax professional. Find Peter Kolchinsky's contact information, phone numbers, home addresses, age, background check, white pages, resumes and CV, places of employment, social media profiles, photos and videos, public records, arrest records, work history, news and business records . Lauras primary responsibilities at RA Capital are to coordinate calendars, events, and company meetings for the TechAtlas division. Emilie has previously held similar roles at FLAG Capital Management and Bain Capital. Brendan holds a MS in Accounting with a concentration in Taxation from Merrimack College and a BA in Economics from University of Massachusetts Amherst. Previously, Michael worked closely with the Investment Team, to originate conviction in potential investments by identifying breakthroughs and putting data into context, as well as advising RA's portfolio companies on many aspects of program and pipeline strategy. Garrett received a BS with honors from the California Institute of Technology while publishing his first paper with Dr. Paul H. Patterson, holds a PhD in Immunology from Stanford University, where he studied hematopoietic stem and progenitor cells with Dr. Irving L. Weissman, and completed his post-doctoral training at Childrens Hospital Boston/Harvard Medical School studying ES/iPSC specification to the hematopoietic fate with Dr. George Q. Daley. Toms primary responsibility is to support all aspects of trade and treasury operations. Prior to RA, Laura was a Principal at MP Healthcare Venture Management. Prior to MPM, she worked as an Executive Assistant at Charles River Ventures. Erin Clutter is the Head of Graphics at RA Capital Management. Peter Kolchinsky Net Worth | Age, Height, Weight, Dating And More Andrews primary responsibility is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Laura works on both public and private investments and serves as a Board Director for Artiva Biotherapeutics, Nimbus Therapeutics, and Acumen Pharmaceuticals. Prior to joining RAVen, Maryann was Director of Business Operations and HR at Q32 Bio where she wore many hats helping to establish the companys business infrastructure including IT, contract management, facilities, administrative support, Human Resources, recruiting, internal communications and was a strong driver of company culture. Bracketts primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Biotech's Dulcius Ex Asperis: The Way Through This Downturn Benjamins primary responsibilities at RA Capital are to coordinate various projects across the Venture Team and oversee their initiation, planning, and execution. Kyle was also the CEO and co-founder of Liquid Light, developer of a proprietary process to make major chemicals from CO2, which was sold to Avantium in 2016. Prior to Relay, she worked as an Executive Assistant at Bullhorn, Inc. Phi holds an Associate in Science Business Administration from Middlesex Community College. In his doctoral research, he investigated clinically translatable treatments for musculoskeletal tissue repair using injectable hydrogels. While in these roles, Emily helped Bluebird grow from 300 to 1000 employees. Ryan Russell is a Fund Accountant at RA Capital Management. Derek works on both public and private investments and serves as a Board Director for 89Bio, Achilles Therapeutics, iTeos Therapeutics, Connect Bio, CANbridge, andWerewolf Therapeutics. Previously, Zach covered the neurology, ophthalmology, and dermatology landscapes. He holds an MD magna cum laude from Harvard-MIT, Program in Health Sciences and Technology, where he was a Paul and Daisy Soros Fellow. Rye Lane to Peter Pan & Wendy: the seven best films to watch on TV this Kat has a BS in Business Administration, majoring in Accounting from the University of Minnesota, Carlson School of Management. Jaimie holds a BA in Biology Boston College, with Minors in Medical Humanities and Sociology, and a Master of Public Health from Boston University School of Public Health. Prior to Tamarack, Brian held roles as Associate Portfolio Manager and Research Analyst, Healthcare, at Sonar Capital Management. Kathryn's primary responsibilities at RA Capital are to coordinate calendars, events, and company meetings for the TechAtlas division. Previously, Rebecca worked as a Senior Associate within RAs TechAtlas division. He worked with Dr. David Raulet and Nobel Laureate Dr. James Allison before which he received a PhD in Molecular Oncology and BSc in Biochemistry from McGill University in Montreal. Medicare 'negotiating' drug prices will hurt Americans, not help - STAT Prior to MRL Ventures, Josh was a Venture Partner with Atlas Venture and a Partner at Prism Venture Partners, focusing on company formation and seed and Series A investing. Generali's No.3 investor Caltagirone withholds backing for 2022 accounts -sources, Musk says Tesla likely to launch full self-drive technology 'this year', Exclusive: JPMorgan employees gripe about Dimon's return-to-office edict, SpaceX rocket explosion illustrates Elon Musk's 'successful failure' formula, Cucinelli posts 33% rise in Q1 sales, confirms 2023 revenue growth forecast, Exclusive-Peter Thiel, Republican megadonor, won't fund candidates in 2024 - sources, Virginia Governor Youngkin 'humbled' by talk of possible presidential run, European Midday Briefing: Mood Brighter After -2-, Tim Cook unveils new Apple store in India, Morgan Stanley's dealmaking CEO Gorman signals more transactions to come, RA Capital Management LP (Private Equity). Bretts primary responsibilities are to advise on regulatory matters and assist in the development, implementation, and testing of the compliance program. Sarah is the only lawyer to have received the NVCAs Outstanding Service Award, for her leadership role in conceiving of and spearheading the NVCA Model Legal Documents. He is co-founder and CEO of Clear Creek Bio, an RA Capital portfolio company. Gabe has a BS in Biology from Cornell University and a PhD in Biology from Northeastern University. Previously, Neil was Director, Business Development and Project Management at CiVentiChem (acquired by Sterling Pharma Solutions). Matts primary responsibilities at RA Capital are to gather team input to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities, and to provide software training and coordinate with outside technology vendors. Prior to MassTech, Natalie held varying Administrative roles at Northeastern University, Framingham Public Schools, and Bright Horizons Family Solutions. So it's not patents holding back production. Brendans primary responsibility is managing all aspects of the tax function. Timothy Noyes is an Advisor for RA Capital Management. Prior to KPMG, TJ worked within the AP/Office Admin function with the Boston Red Sox. He is also active in the firms outreach efforts, speaking frequently both at industry events and in classrooms. Before her time at New Care, she was a Student Researcher at Boston Childrens Hospital Labs of Cognitive Neuroscience. Andrew is a Software Developer at RA Capital Management. MarketScreener: Created by Investors for Investors! Tyler holds a BA in Finance from the University of Massachusetts, Amherst and a certificate in Interactive Design from Rhode Island School of Design. Previously, Emily spent over seven years at Celgene Corporation in positions of increasing responsibility in business development, marketing, operations, and as Principal to the Chairman and CEO. Peter Kolchinsky founded 5 companies, among them: Research Alliance Corp. II, Therapeutics Acquisition Corp. and RA Capital Management LP (Private Equity). Dings primary responsibility at RA Capital is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Nadim completed his BS in Biology at Stony Brook University, received his PhD with Distinction in Microbiology at Columbia University, and was an NRSA Postdoctoral Fellow studying the cell biology of HCV in the laboratory of Nobel Prize winner Charles M. Rice at the Rockefeller University. Joey ONeill is an Investor Services Associate at RA Capital Management. Previously he served as the Director of Pharmaceutical Sciences at the Clinton Health Access Initiative. Mariagrace has a BS in Sociology from Suffolk University. Peter Kolchinsky is a founder and managing partner at RA Capital Management and author of "The Great American Drug Deal" (Evelexa Press, 2020). Her primary responsibilities are to support our Venture Team by coordinating management agendas, calendars, and external events. Peter Kolchinsky Number of IPOs: 18. He most recently served as Chief Medical Officer for Rodin Therapeutics, where he led all clinical development activities from first-in-human through patient studies until the acquisition by Alkermes. Cameron is a Senior Research Assistant at RA Capital Management. Dr. Ryan was also a fellow in Geriatric Psychiatry and Neuropsychiatry at Dartmouth-Hitchcock Medical Center. Any hedge fund managing over $100M is required to submit a 13F form to the SEC which lists their current holdings at the end of each fiscal quarter. Milind has more than 25 years of leadership and operational experience through all stages of drug discovery and development. Megan Lipcsey is an Associate with the TechAtlas division of RA Capital Management. Brendan is a Tax Director at RA Capital Management. Merediths previous experience includes Medical Education Researcher and Medical Scribe positions at BMC Global Inc. and Longwood Pediatrics, respectively. Henry has a BA in Biology & Economics from Dartmouth College. Sarah joined our team from MPM Capital where she served as the COO & General Counsel. Mark began his professional career as a life sciences attorney with the law firm of Hale and Dorr (now WilmerHale). Kyle also recently retired as a Colonel in the US Army Reserve after 24 years of service. Additionally, he is the interim CTO and Board Observer at New Equilibrium Bio. Patrick received his PhD in Natural Sciences, specifically Biochemistry and Molecular Biology, from the Leopold-Franzens University, Innsbruck, Austria. Asia Pacific +65 6212 1000. Prior to MP, she was a Consultant at Clarion Healthcare. Jennas primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Ed began his career working with neurologically active compounds at Allergan, CoCensys, and Serono. Copyright 2001-2023 RA Capital Management, L.P. Peter Kolchinsky Phone Number, Address, Age, Contact Info, Public Emilies primary responsibility at RA Capital is to manage current and potential investor relationships. Before joining Proteon, Tim was the COO of Trine Pharmaceuticals and he held several management positions with GelTex Pharmaceuticals prior to its acquisition by Genzyme. Finally, they made it to the Boston. Prior to Flagship, Emily held roles as Associate Director, Head of Global Talent Acquisition and Associate Director, Recruiting Operations & Analytics at bluebird bio. Mariagrace previously worked as an Executive Assistant at MPM Capital. Tim began his career at Merck & Co., serving in multiple commercial roles in its cardiovascular, gastrointestinal, and managed care divisions. Zach Scheiner is a Principal on the Investment Team at RA Capital Management. Zach previously worked as a Science Officer at the California Institute for Regenerative Medicine. Laura Tadvalkar is a Managing Director on the Venture Team at RA Capital Management. Cristina Ghenoiu is a Principal on the Venture Team at RA Capital Management. Jacquelines primary responsibility is to partner with the Investment Team to develop quantitative analyses that inform investment decisions and improve core processes throughout the firm. Robert also led the Sequencing Operations and Technology Development groups at the Broad for over 12 years, implementing industrial process control methods, developing multiple generations of high-throughput DNA sequencing technologies, and establishing an agile learning culture in the organization. Michael is chair of the Board of Managers of the Harvard Pilgrim Health Care Institute. Prior to Evotec, Cony worked at IGEN, where he was responsible for the marketing strategy of the life sciences division; in addition, he was involved in investor presentations and fundraising. He completed an internship in Internal Medicine and residency in Psychiatry at the University of Utah Health Sciences Center. Angela also gained experience in prior roles as Clinical Trial Manager at Roche, Sarepta, and other companies, and Clinical Research Coordinator at Tufts Medical Center and Dana-Farber Cancer Institute. Angela has a BA in Pre-Medicine and French Studies from the University of Minnesota. Prior to joining RA, Emily was Chief Business Officer of Prevail Therapeutics from the companys inception in 2017 until its acquisition by Eli Lilly in 2021. His research investigated chromatin structure and transcription factor binding. Her primary responsibilities are to assist with all finance operations related to the Firm. Previously, Laura covered hematologic malignancies, cell therapies, retinal diseases, and orphan neurodevelopmental disorders. He was also responsible for initiating the transition of the autoimmunity strategy from one based on systemic immunosuppression to a targeted immunomodulation approach. Prior to Akebia, she gained Administrative and Resource Management experience at Wellington Management and Signature Consultants, respectively. Many of the assets he contributed to within HNDC have been out-licensed to various Cambridge and Boston-based startups and biotech firms for further development. Michael Ryan is an EIR at RA Capital. He completed the Executive Program at Stanford University, Graduate School of Business, as well as the Executive to Leader Institute at Korn/Ferry International. Tylers primary responsibility at RA Capital isdesigning and maintaining the RA Capital website and assisting in the creation and design of interactive platforms at RA Capital and it's portfolio companies founded through the firm's incubator, RA Ventures. Prior to RA, Dan spent three years in Systems Engineer and Technical Consultant roles at Withum Smith + Brown, where he provided cloud and hybrid implementation guidance for clients within industries such as healthcare, construction, and fitness. Maryann Vigliotta is the Vice President of Operations and HR at RA Ventures (RAVen). Dans primary responsibility at RA Capital is to identify compelling opportunities to help facilitate new company creation or investments in emerging seed-stage companies. Currently, he serves as Chief Technology Officer at Danaher, with a focus on new genomic medicines. He holds a MS from Northeastern University and a BA from Hamilton College. Prior to Indigo, Kathryn was Investment Principal at the Massachusetts Clean Energy Center (MassCEC) where she invested in enterprise and consumer-facing clean energy companies, including software and hardware companies focused on utility and grid resilience, grid edge, next-generation renewables, efficient mobility, industrial efficiency, sustainable buildings, and the water-energy nexus. Peyman Hosseinchi is an Associate within the TechAtlas division of RA Capital Management. Mario is responsible for partnering with several of our portfolio companies as Board Member or Technical Advisor. David holds a PhD from Harvard University in Biophysics and a BS in Molecular Biology from Texas A&M University. Ramin is an experienced clinical trialist and previously led global clinical development programs at Akebia Therapeutics and Gilead Sciences. Michael is Executive Vice President at Capstan Therapeutics. Katherine Terranova is an Associate within the TechAtlas division of RA Capital Management. Most of Joels career was spent as a medicinal chemist in pharma, where he capped a 28-year career at Bristol-Myers Squibb by spending the last five years as Vice President and Global Head of Discovery Chemistry, working across all therapeutic areas. Jesse also held research leadership roles at Moderna Therapeutics and Millennium Pharmaceuticals, where he was responsible for developing novel platforms and leading discovery programs. Barrie's 1911 novel. Erich Scheller is the Director of the TechAtlas division of RA Capital Management. Habib brings to RAVen nearly three decades of experience as a strategic leader in Big Pharma and emerging Biotech. Mario received postdoctoral training at the NIH and Mount Sinai School of Medicine in innate immunity and bioinformatics, earned a PhD in microbiology at University of Chile and a MS in Nuclear Physics. He holds a BS in Biology from the College of William and Mary, where he studied the impact of ecological fragmentation on the prevalence of ticks and their bacterial pathogens. As political refugees, the family was placed in Milwaukee, then Pittsburgh. She holds a BS in Finance from Elon University and an MBA from Babson College. Michael is the Chief Financial Officer at RA Capital Management. Peter Kolchinsky's Post - LinkedIn